Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success

Elaine M Sloand1, A J Barrett

  • 1Hematology Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, 10 Center Drive, Bethesda, MD 20892, USA. sloande@nhlbi.nih.gov

Laboratory evidence and clinical evidence suggest that some patients with myelodysplastic syndrome (MDS) have immunologically mediated disease. This article describes the laboratory evidence supporting a role for the immune system in the marrow failure of MDS and clinical trials using IST in these patients.